• Year
• Notes

• 2023
• • First Green Hydrogen Industry focus investment by Center Venture Group. Invested in UMOE, which specializing in hydrogen storage equipment.
  • Center Laboratories Inc. together with Mycenax Biotech (4726 TT) invested in Krisan Biotech aiming to provide CDMO services of ADCs (Antibody Drug Conjugates) for clients around the world with further business expansion.
  • To strengthen the venture capital industry positioning, Center Laboratories Inc. acquired 100% stake holdings in Bioengine Technology Development Inc.

• 2022
• • To seizing market opportunities in high-end medical device CDMO market, Medeon Biodesign Inc. (6499 TT), an investee of the group, announced to acquire MadiBallon and Second Source Medical from Silicon Valley, U.S. Acquisition of three premier medical device manufacturing companies to form an integrated full function service group.
  • JCR Pharmaceuticals invested NTD 1.36 billion in Mycenax Biotech (4726 TT), an investee of our group and became the largest shareholder with 20.48% stockholdings.
  • ToT Biopharm (1875 HK), an investee of the group, post IPO its completed the first round of fund raisings supported by two of its major shareholders, Vivo Capital and Center Laboratories Inc. with premium valuation. The total fund raised was HKD470 million, mainly use for corporate strategic transformation and CDMO business development acceleration.
  • Center Laboratories Inc. merged with its subsidiary “BIOENGINE CAPITAL Inc.,” aiming to become one of the leading professional biotechnology investment holding company.

• 2021
• • ToT Biopharm (1875 HK), an investee to the group, announced that National Medical Products Administration (NMPA) has granted marketing approval for its self-developed product known as Pusintin® (TAB008, Bevacizumab Injection) in China.
  • Mycenax, an investee to the group with devotion to becoming a world-class CDMO company and its expertise in cell therapy and various technological developments has announced the official opening of its operational headquarter and Research & Development center located in Zhu-Bei city.
  • Lumosa Therapeutics (6535 TT), an investee to the group, announced the clearance from the U.S. FDA for a multidose Phase II 2a trial of LT3001, a novel treatment for Acute Ischemic Stroke (AIS) with successful efficacy.

• 2020
• • Center Laboratories Inc.’s two subsidiaries, the AbbVie (ABBV US) and Jacobio Pharmaceutical Group (1167 HK) together formed a global strategic partnership. Through this partnership, both parties will jointly develop and commercialize containing protein tyrosine phosphatase 2 (SHP2) that is considered as anticancer drug target with inhibitors.
  • Center Laboratories Inc.’s novel diabetes drug (CS02) candidate has been proven safe and efficacy on its Phase II clinical trials in multiple countries.
  • Jacobio Pharmaceutical Group (1167 HK), an investee to the group was listed on the Hong Kong Stock Exchange.

• 2019
• • Center Laboratories Inc., and ApicHope（300723.SZ）joint venture to build innovative pediatric drugs utilization platform via strong collaboration between the two companies.
  • Invested on Adimmune (4142 TT) with positive outlook on vaccines as part of National Defense Industry.
  • ToT Biopharm (1875 HK), an investee to the group was listed on the Hong Kong Stock Exchange in November.

• 2018
• • Third reformed and repositioned as professional biotechnology venture capital company that focused on resource integration with synergies.
  • To accelerate growth and market penetration in Biologics Research & Development (R&D) sector, Taiwan Lumosa Therapeutics Co., Ltd. (6535. TT) announced to merge with TPG Biologics, Inc.(6521. TT). Post merger integration, Lumosa Therapeutics aimed to become the first Taiwanese professional pharmaceutical R&D company.
  • Center Laboratories Inc., signed a Memorandum of Understanding (MOU) with CR Pharma (3320 HK) by authorized its self-developed new drug in diabetes (CS02) to be sold exclusively in the China Market.
  • Introduced strategic investment partner from CITIC Agriculture Fund to invest and support Ausnutria (1717 HK) with further global expansion.

• 2017
• • Invested in CVIE Therapeutics Limited, it is a stand-alone drug development company specialized in cardiovascular diseases.
  • Invested in Acepodia (6976 TT), specialized in cellular immunotherapy.
  • Invested in Eusol Biotech (6652 TT), specialized in spinal core injury treatment and sleeping pills.
  • Center Laboratories Inc., supported its two subsidiaries GLAC Biotech (6553 TT) and Glory Biotech (4187 TT) to integrate and create synergies in their probiotics supply-chain in order to achieve economic of scale with growth momentum.
  • Center Laboratories Inc., self-developed new drug product in diabetes (CS02) has been reviewed and approved by the U.S. FDA and Taiwan TFDA. CS02 has entered the phase II clinical trial stage.

• 2016
• • Subsidiaries: Medeon Biodesign Inc. (6499 TT) and Lumosa Therapeutics (6535 TT) officially listed in Over-the-counter (OTC) market.
  • Invested in Biogend Therapeutics (6733 TT), specialized in advanced biologic products for bone and joint repair and restoration.
  • Invested in Ever Supreme Bio Technology (6712 TT), specialized in stem cells and immuno-oncology therapy.
  • Center Laboratories Inc., actively engaged in corporate social responsibility projects. Initiated the first summer internship program (later renamed to Center Laboratories Talents Training Camp)

• 2015
• • Subsidiaries: GLAC Biotech (6553 TT) and TPG Biologics (6521 TT) officially listed in Over-the-counter (OTC) market.
  • Invested in Beijing Jacobio Pharmaceutical Group (1167 HK) – a “Biotechnology Dream Factory”

• 2014
• • Expanded into Big Health that started with Ausnutria (1717 HK) acquisition. Also became the first Taiwanese firm that successfully acquired Hong Kong listed company.
  • Invested in Crown Bioscience Inc. (6554 TT), Biotechnology Fund (MVC) and BRIM Biotech (6885 TT) that specialized in Ophthalmic drugs and immune-oncology.

• 2013
• • One of the key subsidiaries – Mycenax Biotech (4726 TT) officially listed on Over-the-counter (OTC) market.

• 2012
• • Invested in Medical Device industry; investment made in Medeon Biodesign Inc. (6499 TT) and IXensor (6734 TT).
  • Subsidiaries: PharmaEngine (4126 TT) and Glory Biotech (4187 TT) officially listed on Over-the-counter (OTC) market.

• 2011
• • Invested in Lumosa Therapeutics (6535 TT) that dedicated to developing novel therapies and solutions for neurological and oncological diseases with urgent unmet medical need.

• 2010
• • Invested in TOT Biopharm (1875 HK), dedicated to developing and commercializing innovative oncology drugs and therapies.
  • Invested in Glory Biotech (4187 TT) that specialized in development and production of active pharmaceutical ingredients (APIs) in Taiwan.
  • Hsin-Chu Oral Liquid drugs manufacture plant was certified with PIC/S (Taiwan FDA official certifications issued under certificate numbers of AP0256008 and CcGMP000105)
  • Sole company within the Taiwan Biotechnology and pharmaceutical sector that was ranked in 2010 Forbes Best “Under A Billion list highlights the 200 high-performing Asia-Pacific companies with revenue under $1 billion.”

• 2009
• • Established BIOENGINE CAPITAL Inc., to investing and acting as an incubator to support biotechnology companies with growth potential. Invested in PharmaEngine (4126 TT).

• 2008
• • Chairman Lin again helped the Company to undergoes the second reformed and developed differentiation growth strategy after it achieved a remarkable market share of 70% within the domestic oral liquid drugs market in 2008.
    - Organic Growth: To optimize oral drugs product portfolio and further penetrated into new fields product developments such as psychological and CNS (the central nervous system).
    - Strategic Growth: Repositioned as “Biotechnology Industrial Bank” focused in Global and Taiwan Biotechnology investment and become a leading business incubator.
    Based on “Biotechnology Industrial Bank,” the business footprint expanded into proteins and Antibody Drug Conjugate (ADC) development and big health industry, such as investments made in TPG Biologics (6521 TT) and GLAC Biotech (6553 TT).

• 2007
• • Expanded Hsin-Chu plant to help meet fast growing demand in oral liquid drug market.

• 2005
• • Center Laboratories Inc., achieved 50% market shares in Taiwan oral liquid drugs products.

• 2004
• • Expanded footprint in the Biologics sector; investment made in Mycenax (4726 TT).

• 2003
• • Center Laboratories Inc., was listed on the Taiwan Over-the-counter (OTC) in 2003 under the ticker number 4123 with total paid-in capital of NTD 105 million.

• 1998
• • Chairman Rong-Jin, Lin joined Center Laboratories Inc., after joining Chairman Lin reformed and repositioned the company as a professional oral liquid pharmaceutical company specializing in diverse liquid drugs development and manufacturing by adopting the most advanced technology platform and offering wide range of liquid drug solutions for medication purpose.

• 1996
• • Officially renamed into “Center Laboratories Inc.”

• 1988
• • The oral liquid plant located in Hsin-Chu City was approved and certified with GMP inspection.

• 1985
• • In the early stage, Center Laboratories Inc., plant initially located near Jinhua Street, Taipei City. In 1980s, Center Laboratories Inc., reallocated and built new plant in Hsin Chu City in order to prepare for an GMP inspections and certification that complied with government GMP regulations.

• 1959
• • Established in 1959, Center Laboratories Inc., is a Taiwan based pharmaceutical company that produced comprehensive full dosage medicines.